公开(公告)号：WO0156551A3

公开(公告)日：2002-07-11

申请号：PCT/CH0100062

申请日：2001-01-26

Applicant: UNIV ZUERICH ,  SCHMID RALPH A ,  SCHOEDON GABRIELE

Inventor： SCHMID RALPH A ,  SCHOEDON GABRIELE

IPC: A61K31/519 ,  A61K31/708 ,  A61P43/00 ,  A61K31/505 ,  A61K31/70

CPC classification number: A61K31/708 ,  A61K31/519 ,  A61K2300/00

Abstract: Compositions and methods useful for achieving therapeutic effects such as the prevention of vasoconstriction and improvement of the preservation and survival of a transplanted organ. More specifically, the compositions exhibit synergy and comprise amounts of two therapeutic agents selected from the group consisting of BH4 and its precursors , on the one hand and membrane permeable cGMP analogues on the other.

Abstract translation: 用于实现治疗效果的组合物和方法，例如预防血管收缩和改善移植器官的保存和存活。 更具体地，组合物表现出协同作用，并且一方面包含选自BH4及其前体的两种治疗剂的量，另一方面包含另一种膜渗透性cGMP类似物。

公开(公告)号：WO0225279A3

公开(公告)日：2002-07-04

申请号：PCT/EP0110816

申请日：2001-09-19

Applicant: EVOTEC NEUROSCIENCES GMBH ,  UNIV ZUERICH ,  NITSCH ROGER ,  MOHAJERI HASAN ,  WOLLMER AXEL ,  POHLNER JOHANNES

Inventor： NITSCH ROGER ,  MOHAJERI HASAN ,  WOLLMER AXEL ,  POHLNER JOHANNES

IPC: A61K38/17 ,  A61P25/28 ,  G01N33/50

CPC classification number: A61K38/1709

Abstract: The present invention discloses the use of (i) a fragment of the amyloid precursor protein (APP); or, (ii) a derivative of (i); or, (iii) a functional mimetic of (i) or (ii), in the preparation of a medicament for modulating CNS levels and/or activity of a member of the neprilysin family.

Abstract translation: 本发明公开了（i）淀粉样蛋白前体蛋白片段（APP）的用途; 或（ii）（i）的衍生物; 或（iii）（i）或（ii）的功能模拟物在制备调节neprilysin家族成员的CNS水平和/或活性的药物中的用途。

公开(公告)号：WO2013072346A9

公开(公告)日：2013-11-21

申请号：PCT/EP2012072578

申请日：2012-11-14

Applicant: PAREQ AG ,  UNIV ZUERICH

Inventor： BELEUT MANFRED ,  HENCO KARSTEN ,  MOCH HOLGER ,  SCHRAML PETER

IPC: G06F19/24 ,  C12Q1/68 ,  G06F19/18

CPC classification number: G06F19/24 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G06F19/18

Abstract: The present invention describes the use of discrete states and signatures for classifying cancer samples, preferably renal cell cancer samples.

公开(公告)号：WO2013083813A3

公开(公告)日：2013-08-01

申请号：PCT/EP2012074862

申请日：2012-12-07

Applicant: UNIV ZUERICH

Inventor： NEIDHART MICHEL ,  GAY STEFFEN ,  KAROUZAKIS EMMANUEL

IPC: A61K31/155 ,  A61K31/198 ,  A61K31/438 ,  A61K31/444 ,  A61K31/519 ,  A61K31/708 ,  A61K31/714 ,  A61K45/06 ,  A61P19/02 ,  A61P37/02

CPC classification number: A61K31/708 ,  A61K31/155 ,  A61K31/198 ,  A61K31/438 ,  A61K31/444 ,  A61K31/519 ,  A61K31/714 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to inhibitors of SSAT or AMD for the prevention or treatment of rheumatoid arthritis. 4-[(2E)-2-(4-carbamimidoylphenyl)iminohydrazino]-benzamidine (Diminazen) is preferred.

Abstract translation: 本发明涉及用于预防或治疗类风湿性关节炎的SSAT或AMD的抑制剂。 4 - [（2E）-2-（4-甲脒基苯基）亚氨基肼基] - 苄脒（Diminazen）。

公开(公告)号：WO2013061163A2

公开(公告)日：2013-05-02

申请号：PCT/IB2012002905

申请日：2012-10-26

Applicant: BIOGEN IDEC INTERNAT NEUROSCIENCE GMBH ,  UNIV ZUERICH

Inventor： ROGER NITSCH ,  HOCK CHRISTOPH ,  BARENCO MONTRASIO MARIA GRAZIA ,  MONTRASIO FABIO ,  GRIMM JAN ,  BAERISWYL JEAN-LUC

IPC: A61K39/00

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K49/16 ,  A61K51/1018 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2800/2814

Abstract: Provided are novel TDP-43 -specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43 -specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

Abstract translation: 提供了新型TDP-43特异性结合分子，包括多肽，例如人抗体，以及其片段，衍生物和变体。 还提供了与这些TDP-43特异性结合分子相关的方法。 还公开了与TDP-43-特异性结合分子相关的测定，试剂盒和固体支持物，包括多肽，例如人抗体。 TDP-43特异性结合分子，抗体，免疫球蛋白链以及其结合片段，衍生物和变体可分别用于TDP-43靶向免疫治疗和诊断的药物和诊断组合物中。

公开(公告)号：WO2012110968A3

公开(公告)日：2012-11-08

申请号：PCT/IB2012050699

申请日：2012-02-15

Applicant: NOVARTIS AG ,  UNIV ZUERICH ,  RUEHL ANNE ,  ROGLER GERHARD ,  SCHARL MICHAEL

Inventor： RUEHL ANNE ,  ROGLER GERHARD ,  SCHARL MICHAEL

IPC: A61K39/395 ,  A61P1/00 ,  A61P37/06 ,  C07K16/24

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure is in the field of Crohn's disease, in particular, it relates to the treatment of fistulas in Crohn's disease using anti -IL- 13 antibodies. The antibody may be an IgG and in particular may be the anti -IL- 13 antibody 0195i/G12.

Abstract translation: 本公开涉及克罗恩病领域，特别涉及使用抗-IL-13抗体治疗克罗恩病的瘘管。 抗体可以是IgG，特别是抗-IL-13抗体0195i / G12。

公开(公告)号：WO2012095388A2

公开(公告)日：2012-07-19

申请号：PCT/EP2012050243

申请日：2012-01-09

Applicant: UNIV ZUERICH ,  LUTZ HANS ,  HOFMANN REGINA ,  CATTORI VALENTINO

Inventor： LUTZ HANS ,  HOFMANN REGINA ,  CATTORI VALENTINO

IPC: A61K31/513 ,  A61K31/353 ,  A61K31/402 ,  A61K31/4152 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/5365 ,  A61K31/5383 ,  A61K31/541 ,  A61K38/08 ,  A61P31/12 ,  C07K7/06

CPC classification number: A61K31/513 ,  A61K31/353 ,  A61K31/402 ,  A61K31/4152 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/5365 ,  A61K31/5383 ,  A61K31/541 ,  A61K38/08 ,  A61K38/162 ,  C07K7/06 ,  C12N2740/13022

Abstract: The invention provides for inhibitors of HIV integrase, particularly raltegravir, for the treatment of FeLV in felidae, particularly in house cats.

Abstract translation: 本发明提供了HIV整合酶抑制剂，特别是拉尔维地尔，用于治疗felidae，特别是家猫中的FeLV。

公开(公告)号：WO2012047294A3

公开(公告)日：2012-06-21

申请号：PCT/US2011001722

申请日：2011-10-06

Applicant: LUDWIG INST FOR CANCER RES LTD ,  UNIV ZUERICH ,  CHANCELLOR MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD ,  RENNER CHRISTOPH ,  WADLE ANDREAS ,  PAYELI SRAVAN ,  THIEL MARKUS ,  BOWNESS PAUL ,  KOLLNBERGER SIMON

Inventor： RENNER CHRISTOPH ,  WADLE ANDREAS ,  PAYELI SRAVAN ,  THIEL MARKUS ,  BOWNESS PAUL ,  KOLLNBERGER SIMON

IPC: A61K39/395 ,  C07K16/00 ,  C12P21/08

CPC classification number: C07K16/28 ,  C07K16/2833 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76

Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to HLA-B27 heavy-chain homodimers, termed HC-B27, HLA-B272 or B272, particularly recognizing B272 homodimers and which do not recognize or bind HLA-B27 heterotrimers (B27) including HLA-B27 heterotrimers with ß2 microglobulin and peptide. These antibodies are useful in the diagnosis and treatment of HLA-B27 mediated conditions, particularly those associated with B272, the spondylarthritides, a group of related diseases including ankylosing spondylitis (AS) and reactive arthritis (ReA or Reiter's syndrome). The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the present invention may also be used in therapy in combination with chemotherapeutics, immune modulators, anti-inflammatory drugs, NSAIDs and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies HD4, HD5 and HD6 whose sequences are provided herein.

Abstract translation: 特异性结合成员，特别是抗体及其片段，其结合HLA-B27重链同源二聚体，称为HC-B27，HLA-B272或B272，特别是识别B272同型二聚体并且不识别或结合HLA-B27异源三聚体（B27） 包括具有β2微球蛋白和肽的HLA-B27异源二聚体。 这些抗体可用于诊断和治疗HLA-B27介导的病症，特别是与B272相关的那些，脊椎关节炎，一组相关疾病，包括强直性脊柱炎（AS）和反应性关节炎（ReA或Reiter综合征））。 本发明的抗体，可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂，抗炎药物，NSAIDs和/或与其它抗体或其片段组合的治疗中。 这种抗体的例子是本文提供其序列的新型抗体HD4，HD5和HD6。

公开(公告)号：WO2011098367A3

公开(公告)日：2011-12-01

申请号：PCT/EP2011051336

申请日：2011-01-31

Applicant: UNIV ZUERICH ,  HOERSTRUP SIMON P ,  ZEISBERGER STEFFEN M

Inventor： HOERSTRUP SIMON P ,  ZEISBERGER STEFFEN M

IPC: A61L27/14 ,  A01N1/02 ,  A61L27/36 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58

CPC classification number: A61L27/3633 ,  A01N1/0221 ,  A61L27/14 ,  A61L27/38 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/43 ,  A61L2300/602 ,  A61L2300/622

Abstract: The invention pertains to a method for the generation of a living cell based tissue engineered organ and/or tissue analogous structure having mechanical and/or functional properties comprising the steps of providing a organ and/or tissue, wherein the organ and/or tissue has the capacity of functioning or forming the native organ/tissue corresponding to the replacement; and wherein the tissue engineered organ and/or tissue analogous structure is made of/contains material incorporating cryoactive substances and/or particles. Furthermore the invention pertains to a scaffold for use in such a method, to a tissue engineered replacement structure made using this method, in particular in the form of a vessel and/or a heart valve.

Abstract translation: 本发明涉及用于产生具有机械和/或功能特性的基于活细胞的组织工程器官和/或组织类似结构的方法，其包括提供器官和/或组织的步骤，其中所述器官和/或组织具有 功能或形成对应于替代物的天然器官/组织的能力; 并且其中所述组织工程器官和/或组织工程器官和/或组织类似结构由掺入低温活性物质和/或颗粒的材料制成。 此外，本发明涉及用于这种方法的支架，涉及使用该方法制造的组织工程更换结构，特别是以容器和/或心脏瓣膜的形式。

公开(公告)号：WO2010022882A3

公开(公告)日：2010-08-19

申请号：PCT/EP2009006003

申请日：2009-08-19

Applicant: UNIV ZUERICH PROREKTORAT MNW ,  ENG KYNAN ,  PYK PAWEL ,  CHEVRIER EDITH ,  HOLPER LISA ,  KIPER DANIEL

Inventor： ENG KYNAN ,  PYK PAWEL ,  CHEVRIER EDITH ,  HOLPER LISA ,  KIPER DANIEL

IPC: A61F13/06 ,  A61F4/00 ,  G06F3/01

CPC classification number: A63F13/212 ,  A61F4/00 ,  A63F13/06 ,  A63F13/211 ,  A63F13/218 ,  A63F13/235 ,  A63F13/24 ,  A63F2300/1012 ,  G06F3/011 ,  G06F3/017

Abstract: Disclosed are virtual reality systems, in particular immersive virtual reality systems, their parts, construction and use. The systems and/or parts thereof may be used by adults or children, and may be adapted to support, often within a single device, a large range of users of different sizes and medical condition. Users with physical disabilities have difficulties using existing immersive technologies such as those using accessories like head-mounted displays and data gloves. Such users are provided with immersive virtual reality outputs that allow them to see virtual representations of their body parts which appear in a correct spatial position relative to the users' viewpoint.

Abstract translation: 公开了虚拟现实系统，特别是沉浸式虚拟现实系统，其部件，构造和使用。 系统和/或其部件可以由成人或儿童使用，并且可以适于通常在单个装置内支持具有不同尺寸和医疗状况的大范围用户。 身体残疾的用户难以使用现有的身临其境的技术，例如使用头戴式显示器和数据手套等附件。 为这些用户提供身临其境的虚拟现实输出，使他们能够看到他们身体部位的虚拟表示，这些虚拟表示出现在相对于用户视点的正确空间位置上。